Suchergebnisse - "Newell-Price, John"

PubPharm (11)

1

Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia

enthalten in: The Journal of clinical endocrinology and metabolism | 2021

von Merke, D. | Mallappa, A. | Arlt, W. | +14

2

Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3) : a multicentre phase III study with a double-blind, randomised withdrawal phase

enthalten in: The lancet. Diabetes & endocrinology | 2020

von Pivonello, R. | Fleseriu, M. | Newell-Price, J. | +15

ErratumIn: Lancet Diabetes Endocrinol. 2020 Aug 5;:. - PMID 32768393

3

Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease

enthalten in: European journal of endocrinology | 2020

von Newell-Price, J. | Pivonello, R. | Tabarin, A. | +9

4

Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease : A Phase III extension study

enthalten in: Clinical endocrinology | 2019

von Fleseriu, M. | Petersenn, S. | Biller, B. | +9

5

A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly

enthalten in: European journal of endocrinology | 2018

von Trainer, P. | Newell-Price, J. | Ayuk, J. | +14

6

Efficacy and safety of once-monthly pasireotide in Cushing's disease : a 12 month clinical trial

enthalten in: The lancet. Diabetes & endocrinology | 2018

von Lacroix, A. | Gu, F. | Gallardo, W. | +59

CommentIn: Lancet Diabetes Endocrinol. 2018 Jan;6(1):2-3. - PMID 29032080

7

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease : 12-month, Phase III pasireotide study

enthalten in: Endocrine | 2016

von Findling, J. | Fleseriu, M. | Newell-Price, J. | +5

8

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

enthalten in: Drug design, development and therapy | 2015

von Wolin, E. | Jarzab, B. | Eriksson, B. | +16

9

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease : results from a Phase III study

enthalten in: Clinical endocrinology | 2014

von Pivonello, R. | Petersenn, S. | Newell-Price, J. | +80

10

A 12-month phase 3 study of pasireotide in Cushing's disease

enthalten in: The New England journal of medicine | 2012

von Colao, A. | Petersenn, S. | Newell-Price, J. | +78

ErratumIn: N Engl J Med. 2012 Aug 23;367(8):780